Determination of von Willebrand factor for the confirmation of von Willebrand's disease in Nicaragua
Vol. 24 No. 1 (2020), Brief communications
Vol. 24 No. 1 (2020)

Determination of von Willebrand factor for the confirmation of von Willebrand's disease in Nicaragua

Brief communications
Published 2020-05-15
Allan Pernudy
Laboratorio de Biología Molecular “MA. Elmer Cisneros” in memoriam, Instituto Politécnico de la Salud, Universidad Nacional Autónoma de Nicaragua
Dania Gutiérrez
Aryeris Espinoza
René Berrios
Orlando Bonilla
Revista Hematología ENERO - ABRIL 2020
pdf (Español (España))

Keywords

von Willebrand disease, Antigenic von Willebrand factor, Hemostasis.

How to Cite

Pernudy, A., Gutiérrez, D., Espinoza, A., Berrios, R., & Bonilla, O. (2020). Determination of von Willebrand factor for the confirmation of von Willebrand’s disease in Nicaragua. Journal of Hematology, 24(1), 91–94. Retrieved from https://revistahematologia.com.ar/index.php/Revista/article/view/248
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Von Willebrand's disease is the most frequent hemorrhagic diathesis worldwide affecting men and women. Currently, there are 3 types of von Willebrand ´s disease: type 1, 2A, 2B, 2M, 2N, and 3, with type 1 being the most frequent. In Nicaragua the diagnosis of this coagulopathy is based on basic hemostasis tests; supposedly leading to inadequate diagnosis. The present study determined the antigenic von Willebrand factor (vWF) in patients with suspected of von Willebrand disease registered in the National Blood Bank; Managua, Nicaragua in 2017. 
A descriptive cross-sectional study was conducted with 39 patients with suspected von Willebrand’s disease. A commercial kit was used to determine the plasma concentration of von Willebrand factor. It
was obtained that of 69% of the analyzed individuals presented normal concentrations of von Willebrand factor. Only in the remaining 31% of the patients the von Willebrand disease was confirmed by decreased von Willebrand factor levels.

pdf (Español (España))

References

1. Hernández EZ, Zavala CH, Quintana SG, Reyes EM. Enfermedad de von Willebrand: Biología molecular y diagnóstico. ELSEVIER. 2015; 83:255-264.
2. Lillicrap D. Ciencia Básica, diagnóstico y tratamiento médico de la Enfermedad de von Willebrand. Federación Mundial de Hemofilia. 2008, 35 (5-7) 2-13.
3. Batlle J, Pérez-Rodriguez A, Costa-Pinto J et al. Avances en el síndrome de von Willebrand o enfermedad de von Willebrand adquirida: aspectos más novedosos. Haematologica. 2016; 96: 35-42.
4. Leebeek, FW, Eikenboom JC. Enfermedad von Willebrand. NEJM. 2016; 375:2067-2080.
5. Verdugo P, Morales M, Quiroga T. Correlación clínica y de laboratorio en pacientes pediátricos portadores de Enfermedad de von Willebrand. BVS. Chile. 2005; 2.
6. Manucci, PM. Tratamiento de la Enfermedad von Willebrand. NEJM. 2004; 351:683-694. Disponible en https://www.nejm.org/doi/full/10.1056/NEJMra040403
7. Stufano F, Baronciani L, Peyvandi F. Diagnóstico de la Enfermedad von Willebrand: Caracterización fenotípica. FMH. 2017;55: 1-24

All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar

Downloads

Download data is not yet available.